Cardiovascular repair with bone marrow-derived cells

• Type of Material: Article
• Authors: Woan-Sang Kim, Emory University; Sangho Lee, Emory University; Young-sup Yoon, Emory University
• Language: English
• Date: 2013-06-25
• Publisher: Synapse
• Publication Version: Final Published Version
• Copyright Statement: © 2013 Korean Society of Hematology
• License: Creative Commons Attribution-Noncommercial 3.0 Unported
• Final Published Version (URL): http://synapse.koreamed.org/DOIx.php?id=10.5045/br.2013.48.2.76
• Title of Journal or Parent Work: Blood Research
• ISSN: 2287-979X
• Volume: 48
• Issue: 2
• Start Page: 76
• End Page: 86
• Grant/Funding Information: This work was supported in part by NIH grants DP3DK094346, RC1GM092035; and NIH contract, HHSN268201000043C (Program of Excellence in Nanotechnology Award); Wallace H. Coulter Translational Research Grant; Pilot grant of Emory-Georgia Tech Regenerative Medicine; NSF-EBICS (Emergent Behaviors of Integrated Cellular Systems) grant, CBET-0939511, USA; and Stem Cell Research Center of the 21st Century Frontier Research Program grant SC4300, funded by the Ministry of Science and Technology, Republic of Korea.
• Keywords: Bone marrow; Cardiovascular repair; Paracrine; CD31; Cell therapy; Neovascularization
• Research Categories: Biology, Cell; Health Sciences, Medicine and Surgery

Abstract

While bone marrow (BM)-derived cells have been comprehensively studied for their propitious pre-clinical results, clinical trials have shown controversial outcomes. Unlike previously acknowledged, more recent studies have now confirmed that humoral and paracrine effects are the key mechanisms for tissue regeneration and functional recovery, instead of transdifferentiation of BM-derived cells into cardiovascular tissues. The progression of the understanding of BM-derived cells has further led to exploring efficient methods to isolate and obtain, without mobilization, sufficient number of cell populations that would eventually have a higher therapeutic potential. As such, hematopoietic CD31+ cells, prevalent in both bone marrow and peripheral blood, have been discovered, in recent studies, to have angiogenic and vasculogenic activities and to show strong potential for therapeutic neovascularization in ischemic tissues. This article will discuss recent advancement on BM-derived cell therapy and the implication of newly discovered CD31+ cells.